APGE Company Profile and Key Details

APGE has shown sold momentum, gaining 5.65% over the past week and 48.76% over the past quarter, though year-to-date performance is up 8.69%. Short-term trend indicators are mixed aligned (SMA20 2.49%, SMA50 -5.69%, SMA200 30.48%). The stock’s 14-day RSI is 48.05 (neutral), while the ATR of 3.67 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -18.29% below its high and over 163.7% above its low. Average 10-day trading volume of 695.22 thousand shares is below the 3-month average of 920.13 thousand, indicating normal recent market interest.

Apogee Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.02. This means the shares are trading above this model’s fair value.

Apogee Therapeutics, Inc. (NASDAQ:APGE) closed at $83.55 USD, gaining $2.80 (3.47%) from the previous close of $80.75. The stock is currently mid-range between its 52-week high and low $34.34 and $95.31. With a market capitalization of about $5.17 billion, Apogee Therapeutics, Inc. is classified as a mid-cap and shows market-like volatility (beta ~1.02). Key stats such as the average daily volume over the past year has been around 932.42 thousand shares, volume is running light vs its 52-week average. Headquartered in Waltham, MA, Apogee Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Michael Thomas Henderson, the company employs approximately 196 people and listed since July 14, 2023. Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications.

Wall Street analysts project EPS growth of -21.06% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 6 Strong Buy ratings, 13 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $160.00 to $60.00. The high target offers 91.5% upside. The low target suggests -28.19% downside. The mean target is $109.45. This offers 31.0% upside. Apogee Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended March 02, 2026, missed forecasts by -1.9%. The prior quarter beat by -2.63%. Over the last six quarters, Apple has recorded several small beats. These include 17.81% in November 12, 2024.

Apogee Therapeutics, Inc. has 61.85 million shares outstanding. The public float is 53.10 million shares, elevated short interest at 20.02% of float. This equals 9.57 million shares. The short ratio is 8.07 days. Institutional investors hold 120.46% of the float. Insiders own 6.2%. HENDERSON MICHAEL THOMAS holds 1.13 million shares, Shah Nimish P has 365.85 thousand shares and Fairmount Funds Management LLC has 298.65 thousand shares. Over the past six months, insider transactions show net selling. They sold 1.83 million shares across 26 transactions.

Our AI price prediction model suggests that Apogee Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.47%, with price expected at $83.16 by May 18, 2026, within a range of $78.62 to $87.35 3-Month Outlook: Projected rise of 29.92%, reaching $108.55 by July 31, 2026, with a range of $106.67 to $110.48. 1-Year Outlook: Projected gain of 10.87%, with price at $92.63 by May 04, 2027, within a range of $88.34 to $98.42.

Apogee Therapeutics, Inc. (NASDAQ:APGE) shares are flat 8.69% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Apogee Therapeutics, Inc. trading at a premium to the broader market with a P/E of -19.82. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $101.80, suggesting 21.84% upside. Our AI forecast model points to short-term weakness (-0.47% over two weeks), a medium-term rise (29.92% over three months), and a longer-term gain (10.87% over one year), with expected trading ranges indicating moderate volatility.

Apogee Therapeutics, Inc. trades at a P/E ratio of -19.82, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 5.61 trading at moderately above to book value. The P/FCF stands at -22.22, also below market averages.